Weekly Investment Analysts’ Ratings Changes for Lantern Pharma (LTRN)

Lantern Pharma (NASDAQ: LTRN) recently received a number of ratings updates from brokerages and research firms:

• 5/23/2026 – Lantern Pharma was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/22/2026 – Lantern Pharma was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 5/9/2026 – Lantern Pharma was upgraded by Wall Street Zen to “sell”.
• 5/7/2026 – Lantern Pharma was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.

Insiders Place Their Bets

In other news, Director D Jeffrey Keyser acquired 48,544 shares of the company’s stock in a transaction dated Tuesday, May 12th. The stock was acquired at an average cost of $2.06 per share, for a total transaction of $100,000.64. Following the acquisition, the director directly owned 94,303 shares in the company, valued at approximately $194,264.18. This represents a 106.09% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Lee Troy Schalop purchased 48,544 shares of the stock in a transaction that occurred on Tuesday, May 12th. The stock was bought at an average price of $2.06 per share, with a total value of $100,000.64. Following the completion of the acquisition, the director owned 48,544 shares in the company, valued at $100,000.64. This represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Corporate insiders own 8.50% of the company’s stock.

Lantern Pharma, Inc is a clinical-stage oncology company leveraging artificial intelligence (AI) and machine learning to accelerate the discovery and development of targeted cancer therapies. Headquartered in Dallas, Texas, Lantern Pharma’s proprietary RADR® platform integrates large-scale genomic, transcriptomic and chemical data to identify novel drug candidates and predict patient populations most likely to benefit from treatment.

The company’s pipeline focuses on molecules designed to address cancers with high unmet medical need.